论文部分内容阅读
目的:观察美托洛尔联合曲美他嗪治疗冠心病心力衰竭的效果。方法:随机将我院2016年3月~2017年3月收治的78例冠心病心力衰竭患者分为两组,每组39例。对照组行常规治疗,观察组在对照组的基础上给予美托洛尔与曲美他嗪,比较两组临床效果。结果:观察组总有效率、心功能各指标等均明显优于对照组,差异有显著性意义(P<0.05)。两组均未发现严重不良反应。结论:美托洛尔联合曲美他嗪可有效治疗冠心病心力衰竭,它可明显改善心脏功能,且不良反应少,值得临床中推广。
Objective: To observe the effect of metoprolol combined with trimetazidine in the treatment of heart failure of coronary heart disease. Methods: 78 cases of CHD patients with heart failure treated in our hospital from March 2016 to March 2017 were randomly divided into two groups, 39 cases in each group. The control group received routine treatment. The observation group was given metoprolol and trimetazidine on the basis of the control group, and the clinical effects were compared between the two groups. Results: The total effective rate and the indexes of cardiac function in the observation group were significantly better than those in the control group, the difference was significant (P <0.05). No serious adverse reactions were found in either group. Conclusion: Metoprolol combined with trimetazidine can effectively treat heart failure due to coronary heart disease. It can significantly improve cardiac function with less adverse reactions and is worthy of promotion in clinic.